Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies

Summary Induction of broadly neutralizing antibodies (bnAbs) is a primary goal of HIV vaccine development. VRC01-class bnAbs are important vaccine leads because their precursor B cells targeted by an engineered priming immunogen are relatively common among humans. This priming immunogen has demonstrated the ability to initiate a bnAb response in animal models, but recall and maturation toward bnAb development has not been shown. Here, we report the development of boosting immunogens designed to guide the genetic and functional maturation of previously primed VRC01-class precursors. Boosting a transgenic mouse model expressing germline VRC01 heavy chains produced broad neutralization of near-native isolates (N276A) and weak neutralization of fully native HIV. Functional and genetic characteristics indicate that the boosted mAbs are consistent with partially mature VRC01-class antibodies and place them on a maturation trajectory that leads toward mature VRC01-class bnAbs. The results show how reductionist sequential immunization can guide maturation of HIV bnAb responses.

[1]  Jerome H. Kim,et al.  Impact of Clade, Geography, and Age of the Epidemic on HIV-1 Neutralization by Antibodies , 2014, Journal of Virology.

[2]  Tongqing Zhou,et al.  Structure and immune recognition of trimeric prefusion HIV-1 Env , 2014, Nature.

[3]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[4]  Han Gao,et al.  Antibody 8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike. , 2014, Cell reports.

[5]  D. Richman,et al.  Rapid evolution of the neutralizing antibody response to HIV type 1 infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Joseph G. Jardine,et al.  HIV-1 broadly neutralizing antibody precursor B cells revealed by germline-targeting immunogen , 2016, Science.

[7]  C Oseroff,et al.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. , 1994, Immunity.

[8]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[9]  Young Do Kwon,et al.  Enhanced Potency of a Broadly Neutralizing HIV-1 Antibody In Vitro Improves Protection against Lentiviral Infection In Vivo , 2014, Journal of Virology.

[10]  Barney S. Graham,et al.  Mechanism of Neutralization by the Broadly Neutralizing HIV-1 Monoclonal Antibody VRC01 , 2011, Journal of Virology.

[11]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[12]  Cinque S. Soto,et al.  Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors , 2015, Cell.

[13]  Chaim A. Schramm,et al.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies , 2014, Nature.

[14]  Holly Janes,et al.  Tiered Categorization of a Diverse Panel of HIV-1 Env Pseudoviruses for Assessment of Neutralizing Antibodies , 2009, Journal of Virology.

[15]  D. Dimitrov Therapeutic antibodies, vaccines and antibodyomes , 2010, mAbs.

[16]  N. Haigwood,et al.  Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens , 2016, The Journal of Immunology.

[17]  D. Burton,et al.  Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design. , 2015, Immunity.

[18]  B A McKinney,et al.  High-throughput antibody sequencing reveals genetic evidence of global regulation of the naïve and memory repertoires that extends across individuals , 2012, Genes and Immunity.

[19]  M. Nussenzweig,et al.  Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia , 2013, Nature.

[20]  Daniel G. Brown,et al.  PANDAseq: paired-end assembler for illumina sequences , 2012, BMC Bioinformatics.

[21]  James E. Crowe,et al.  Location and length distribution of somatic hypermutation-associated DNA insertions and deletions reveals regions of antibody structural plasticity , 2012, Genes and Immunity.

[22]  David Nemazee,et al.  Rational immunogen design to target specific germline B cell receptors , 2012, Retrovirology.

[23]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[24]  B. Haynes,et al.  HIV‐1 neutralizing antibodies: understanding nature's pathways , 2013, Immunological reviews.

[25]  Chaim A. Schramm,et al.  Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus , 2013, Nature.

[26]  R. Koup,et al.  Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know , 2004, Nature Medicine.

[27]  Ron Diskin,et al.  Restricting HIV-1 pathways for escape using rationally designed anti–HIV-1 antibodies , 2013, The Journal of experimental medicine.

[28]  Dennis R Burton,et al.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design. , 2016, Annual review of immunology.

[29]  L. Stamatatos,et al.  Engineering, Expression, Purification, and Characterization of Stable Clade A/B Recombinant Soluble Heterotrimeric gp140 Proteins , 2011, Journal of Virology.

[30]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[31]  Gwo-Yu Chuang,et al.  Antibodies VRC01 and 10E8 Neutralize HIV-1 with High Breadth and Potency Even with Ig-Framework Regions Substantially Reverted to Germline , 2014, The Journal of Immunology.

[32]  L. Stamatatos,et al.  Correction: Recombinant HIV Envelope Proteins Fail to Engage Germline Versions of Anti-CD4bs bNAbs , 2013, PLoS Pathogens.

[33]  John P. Moore,et al.  Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex , 2014, Proceedings of the National Academy of Sciences.

[34]  John P. Moore,et al.  Cryo-EM Structure of a Fully Glycosylated Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[35]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[36]  Dennis R. Burton,et al.  Clonify: unseeded antibody lineage assignment from next-generation sequencing data , 2016, Scientific Reports.

[37]  David Nemazee,et al.  Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen , 2015, Science.

[38]  J. Hoxie,et al.  Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor , 2014, Science Translational Medicine.

[39]  Michael S. Seaman,et al.  Therapeutic Efficacy of Potent Neutralizing HIV-1-Specific Monoclonal Antibodies in SHIV-Infected Rhesus Monkeys , 2013, Nature.

[40]  Martin A. Nowak,et al.  Antibody neutralization and escape by HIV-1 , 2003, Nature.

[41]  Young Do Kwon,et al.  Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies. , 2013, Immunity.

[42]  L. Stamatatos,et al.  Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies , 2013, The Journal of experimental medicine.

[43]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[44]  Renate Kunert,et al.  Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.

[45]  Marcel Martin Cutadapt removes adapter sequences from high-throughput sequencing reads , 2011 .

[46]  L. Stamatatos,et al.  Antigen modification regulates competition of broad and narrow neutralizing HIV antibodies , 2014, Science.

[47]  D. Burton,et al.  Minimally Mutated HIV-1 Broadly Neutralizing Antibodies to Guide Reductionist Vaccine Design , 2016, PLoS pathogens.

[48]  J. Mascola,et al.  Key gp120 Glycans Pose Roadblocks to the Rapid Development of VRC01-Class Antibodies in an HIV-1-Infected Chinese Donor. , 2016, Immunity.

[49]  Jerome H. Kim,et al.  HIV-1 vaccines , 2014, Human vaccines & immunotherapeutics.

[50]  John P. Moore,et al.  HIV-1 Envelope Trimer Design and Immunization Strategies To Induce Broadly Neutralizing Antibodies. , 2016, Trends in immunology.

[51]  L. Stamatatos,et al.  Specifically modified Env immunogens activate B-cell precursors of broadly neutralizing HIV-1 antibodies in transgenic mice , 2016, Nature Communications.

[52]  Michael S. Seaman,et al.  Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117 , 2015, Nature.

[53]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[54]  T. Kepler,et al.  Envelope Deglycosylation Enhances Antigenicity of HIV-1 gp41 Epitopes for Both Broad Neutralizing Antibodies and Their Unmutated Ancestor Antibodies , 2011, PLoS pathogens.

[55]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[56]  J. Mascola,et al.  Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1 , 2010, Journal of Virology.

[57]  Lynn Morris,et al.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies , 2015, Nature Medicine.

[58]  Alessandro Sette,et al.  The optimization of helper T lymphocyte (HTL) function in vaccine development , 1998, Immunologic research.

[59]  Wayne C Koff,et al.  Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. , 2014, Immunity.

[60]  John P. Moore,et al.  A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies , 2013, PLoS pathogens.

[61]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[62]  G. Debnath,et al.  D-101 HIV-1 neutralizing antibodies induced by native-like envelope trimers , 2016 .

[63]  Jonathan R. McDaniel,et al.  Structures of HIV-1-Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design , 2015, Nature Structural &Molecular Biology.

[64]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[65]  Scott D Boyd,et al.  Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies. , 2014, Cell host & microbe.

[66]  John P. Moore,et al.  Crystal Structure of a Soluble Cleaved HIV-1 Envelope Trimer , 2013, Science.

[67]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[68]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[69]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.